Parallel screening: A novel concept in pharmacophore modeling and virtual screening

被引:86
作者
Steindl, Theodora M.
Schuster, Daniela
Laggner, Christian
Langer, Thierry
机构
[1] Univ Innsbruck, Comp Aided Mol Design Grp, Inst Pharm, A-6020 Innsbruck, Austria
[2] CMBI, A-6020 Innsbruck, Austria
[3] Inte Ligand GmbH, A-2344 Maria Enzersdorf, Austria
关键词
D O I
10.1021/ci6002043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Parallel screening comprises a novel in silico method to predict the potential biological activities of a compound by screening it with a multitude of pharmacophore models. Our aim is to provide a fast, large-scale system that allows for virtual activity profiling. In this proof of principle study, carried out with the software tools LigandScout and Catalyst, we present a model work for the application of parallel pharmacophore-based virtual screening on a set of 50 structure-based pharmacophore models built for various viral targets and 100 antiviral compounds. The latter were screened against all pharmacophore models in order to determine if their biological targets could be correctly predicted via an enrichment of corresponding pharmacophores matching these ligands. The results demonstrate that the desired enrichment, that is, successful virtual activity profiling, was achieved for approximately 90% of all input molecules. We discuss descriptors for output validation, as well as various aspects influencing the analysis of the obtained activity profiles, and the effect of the utilized search modus for screening.
引用
收藏
页码:2146 / 2157
页数:12
相关论文
共 42 条
[1]  
Alymova I. V., 2005, Current Drug Targets - Infectious Disorders, V5, P401, DOI 10.2174/156800505774912884
[2]   Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 [J].
Balzarini, J .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) :921-944
[3]   Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT [J].
Barreca, ML ;
Rao, A ;
De Luca, L ;
Zappalà, L ;
Monforte, AM ;
Maga, G ;
Pannecouque, C ;
Balzarini, J ;
De Clercq, E ;
Chimirri, A ;
Monforte, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (09) :3433-3437
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]  
Bohm H. J., 1996, WIRKSTOFFDESIGN, P451
[6]   Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase [J].
Chand, P ;
Kotian, PL ;
Morris, PE ;
Bantia, S ;
Walsh, DA ;
Babu, YS .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (07) :2665-2678
[7]   HUMAN RHINOVIRUS-14 COMPLEXED WITH ANTIVIRAL COMPOUND R-61837 [J].
CHAPMAN, MS ;
MINOR, I ;
ROSSMANN, MG ;
DIANA, GD ;
ANDRIES, K .
JOURNAL OF MOLECULAR BIOLOGY, 1991, 217 (03) :455-463
[8]  
CLEMENT OO, 2004, P 3 PHARM PROF DRUG, P381
[9]   Robust ligand-based modeling of the biological targets of known drugs [J].
Cleves, Ann E. ;
Jain, Ajay N. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (10) :2921-2938
[10]  
Condon Stephen M., 2005, Current Medicinal Chemistry - Anti-Infective Agents, V4, P99, DOI 10.2174/1568012053506972